PYLARIFY

Product

Last mentioned: Feb 26, 2026

Stories mentioning PYLARIFY 2

earnings Neutral

Mid-Cap Biotech Resilience: Lantheus and Heron Navigate Mixed Q4 Results

Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter results for 2025, characterized by revenue growth offset by margin pressures. Crucially, both firms took the rare step of introducing fiscal year 2026 guidance, signaling a strategic shift toward long-term stability in the radiopharmaceutical and acute care markets.

2 sources
pharma Neutral

Q4 2025 Biotech Earnings: Delcath and Peers Face Critical Commercial Milestones

As the Q4 2025 earnings season commences, Delcath Systems, Butterfly Network, Heron Therapeutics, and Lantheus Holdings are under intense scrutiny regarding their commercial execution and path to profitability. Investors are particularly focused on Delcath's HEPZATO KIT rollout and Lantheus's ability to maintain its dominance in the competitive radiopharmaceutical market.

4 sources